The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas

Investigational New Drugs

Volumn 26, Issue 2, 2008, Pages 175-181

  Zucali, Paolo Andrea ^a   Bertuzzi, Alexia ^a   Parra, Hector Jose Soto ^b   Campagnoli, Elisabetta ^a   Quagliuolo, Vittorio ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b Azienda Ospedaliera Garibaldi   (Italy)

Author keywords

DTIC; Second third line chemotherapy; Soft tissue sarcoma

Indexed keywords

DACARBAZINE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SARCOMA; TREATMENT OUTCOME;

EID: 40549129414     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9086-z     Document Type: Article

References (45)

1. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545
2. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, Parkinson DR (1993) Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269-1275
3. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL (1993) An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276-1285
4. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS (1997) High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J Clin Oncol 15:2378-2384
5. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J (1995) High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13:1600-1608
6. Palumbo R, Palmeri S, Antimi M, Gatti C, Raffo P, Villani G, Toma S (1997) Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol 8:1159-1162
7. Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, van Oosterom A, Radford JA, Svancarova L, Krzemienlecki K, Hermans C, van Glabbeke M, Oosterhuis JW, Verweij J (2000) Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36:61-67
8. Gottlieb JA, Benjamin RS, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, Rivkin SE, Bodey GP, Rodriguez V, Blumenschein GR, Saiki JH, Coltman C, Burgess MA, Sullivan P, Thigpen T, Bottomley R, Balcerzak S, Moon TE (1976) Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 60:199-203
9. Buesa JM, Mouridsen HT, van Oosterom AT, Verweij J, Wagener T, Steward W, Poveda A, Vestlev PM, Thomas D, Sylvester R (1991) High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann Oncol 2:307-309
10. Buesa JM, Gracia M, Valle M, Estrada E, Hidalgo OF, Lacave AJ (1984) Phase I trial of intermittent high-dose dacarbazine. Cancer Treat Rep 68:499-504
11. Demetri GD, Elias AD (1995) Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 9:765-785
12. National Cancer Institute. Common toxicity criteria manual, version 2.0, June 1, 1999. Available from: http://ctep.cancer.gov/reporting/ctc.html
13. Kaplan EL, Meier P (1958) Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457-481
14. Verweij J, Mouridsen HT, Nielssen OS, Woll PJ, Somers R, van Oosterom AT, Van Glabbeke M, Tursz T (1995) The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol 20:193-201
15. Budd GT (1995) Palliative chemotherapy of adult soft tissue sarcomas. Semin Oncol 22:30-34
16. Patel SR, Benjamin RS (1999) New chemotherapeutic strategies for soft tissue sarcomas. Semin Surg Oncol 17:47-51
17. Singer S, Demetri GD, Baldini EH, Fletcher CD (2000) Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 1:75-85
18. Maki RG (2002) Multidisciplinary management of soft-tissue sarcomas. Cancer Invest 20:818-824
19. Clark MA, Fisher C, Judson I, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353:701-711
20. Van Hoesel QG, Verweij J, Catimel G, Clavel M, Kerbrat P, van Oosterom AT, Kerger J, Tursz T, van Glabbeke M, van Pottelsberghe C, le Bail N, Mouridsen H (1994) EORTC Soft Tissue and Bone Sarcoma Group: Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 5:539-542
21. Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, Seynaeve C, di Paola ED, van Glabbeke M, Tonelli D, Judson IR (2000) Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 18:2081-2086
22. Reichardt P, Oechsle K, Pink D, Bokemeyer C, Schneller F, Issels R, Kanz L, Hartmann JT (2003) An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 21:481-486
23. Fidias P, Demetri GD, Harmon DC (1998) Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH/Dana Farber/Partner's Cancer Care Study. Proc Am Soc Clin Oncol 17:513a, (abstr 1977)
24. Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, Inbar M (2000) Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 45:177-181
25. Späth-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K (2000) Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 11:325-329
26. Svancarova L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, Keizer HJ, Hermans C, van Glabbeke M, Verweij J, Hogendoorn PC, Nielsen OS (2002) Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38:556-559
27. Blay JY, Judson I, Rodenhuis S, Hermans C, Smith M, van Glabbeke M, Verweij J (1999) Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anticancer Drugs 10:873-877
28. Woll PJ, Judson I, Lee SM, Rodenhuis S, Nielsen OS, Buesa JM, Lorigan PC, Leyvraz S, Hermans C, van Glabbeke M, Verweij J (1999) Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 35:410-412
29. Garcia del Muro X, Lopez-Pousa A, Martin J, Buesa JM, Martinez-Trufero J, Casado A, Poveda A, Cruz J, Bover I, Maurel J (2005) Spanish Group for Research on Sarcomas: A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 104:1706-1712
30. Kollmannsberger C, Brugger W, Hartmann JT, Maurer F, Bohm P, Kanz L, Bokemeyer C (1999) Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 10:453-456
31. Garcia AA, Kempf RA, Rogers M, Muggia FM (1998) A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann Oncol 9:1131-1133
32. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL (2004) Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22:890-899
33. Tursz T (1996) High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. Semin Oncol 23:34-39
34. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS (2005) Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23:576-584
35. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M, Cvitkovic E (2001) Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 19:1248-1255
36. Demetri GD (2002) ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs 13:S7-S9
37. George S, Maki R, Harmon D, Supko J, Morgan J, Seiden M, Buonann M, Griffin J, Moutsiolis A, Lopez T, Guzman C, Jimeno J, Demetri GD (2002) Phase II study of ecteinascidin-743 (ET-743) given by 3-hour IV infusion in patients (pts) with soft tissue sarcomas (STS) failing prior chemotherapies. Proc Am Soc Clin Oncol 21:408a, (abstr 1630)
38. Casali P, Casanova M, Dileo P, Ferrari S, Bacci G, Picci P, Marsoni S, Jimeno J, Riccardi R (2003) Activity of ecteinascidin-743 (ET, trabectedin) 3-hour infusion in adult and childhood small round cell sarcomas. Proc Am Soc Clin Oncol 22:240, (abstr)
39. Fossati R, Confalonieri C, Apolone G, Cavuto S, Garattini S (2002) Does a drug do better when it is new? Ann Oncol 13:470-473
40. Santoro A (1999) Advanced soft tissue sarcoma: how many more trials with anthracyclines and ifosfamide? Ann Oncol 10:151-154
41. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8:595-602
42. Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, Schwartz GK, Casper ES (1999) Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86:2034-2037
43. Skubitz KM, Haddad PA (2005) Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104:361-366
44. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824-2831
45. Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, Zaino RJ (1983) A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52:626-632